Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
|
31139940 |
2020 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our findings were substantiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ERα/Src and ERα/PI3K expression, hallmarks of nongenomic estrogen signaling, reinforcing the link between IGF-1R and mERα.
|
30692633 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In pre-clinical models, co-existence of Human Epidermal Growth Factor Receptor-2 (HER2)-amplification and PI3K catalytic subunit (PIK3CA) mutations results in aggressive, anti-HER2 therapy-resistant breast tumors.
|
31219154 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Additionally, associations were found for EGFR variations in lung tumors and PIK3CA variations in breast tumors.
|
31100334 |
2019 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It is unknown whether changes in the PI3K pathway result in a different composition of the breast tumor microenvironment.
|
31391067 |
2019 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that the association between breast tumor EGFR expression and high FDG uptake might be contributed by stimulation of the PI3K pathway downstream of EGFR activation.
|
31532771 |
2019 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.
|
29719270 |
2018 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages.
|
29880805 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
To demonstrate its ability on a new dataset, we profile 33 genes/nodes of the PI3K pathway in 1734 FFPE breast tumors and create a four-subnetwork prediction model.
|
30420699 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In summary, our study supports a role for NEK9 and MAP2K4 in mediating buparlisib resistance and demonstrates the value of unbiased omic analyses in uncovering resistance mechanisms to targeted therapy.<b>Significance:</b> Integrative phosphoproteogenomic analysis is used to determine intrinsic resistance mechanisms of triple-negative breast tumors to PI3K inhibition.<i></i>.
|
29472518 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We hypothesized that exercise training might reduce breast tumour growth by inducing oxytocin (OT) secretion and its related signalling pathways, such as PI3K/Akt and ERK.
|
29143998 |
2018 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In the current study, we found that PI3K inhibition by GDC-0941 increased macrophage infiltration and induced the expression of macrophage-associated cytokines and chemokines in the mouse 4T1 breast tumor model.
|
30042442 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We aimed to evaluate the expression of hormone and insulin-related proteins within or related to the PI3K and MAPK pathway in breast tumors of women with or without diabetes mellitus, treated with or without insulin (analogues).
|
29486734 |
2018 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In this study, we present an integrated genomic analysis based on the use of a PI3K gene expression signature as a framework to analyze orthogonal genomic data from human breast tumors, including RNA expression, DNA copy number alterations, and protein expression.
|
28176176 |
2017 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
<i>in-silico</i> analysis finds that CXCL12-CXCR4 is associated with an increased expression of PDZK1, PI3k and Akt which lead the breast tumor towards metastasis.
|
28929029 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor-2 (HER2) amplification/overexpression (HER2+) frequently co-occurs with PI3K pathway activation in breast tumors.
|
26500061 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This provides a rationale for the combined targeting of p110α with IGF1R or p110β in patients with breast tumors harboring PIK3CA mutations.
|
27048245 |
2016 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We showed that hyperphosphorylation in ATP citrate lyase (ACL) occurs frequently in human breast tumors and correlates well with HER2+ and/or PIK3CA-mutant (HER2+/PIK3CAmut) status in breast tumor cell lines.
|
27015560 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations were observed in 23.2 % (43/185) of breast tumor samples.
|
27282497 |
2016 |
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Consistently, in human breast tumours, upregulation of NRF2 targets is associated with PI(3)K pathway mutation status and oncogenic Akt activation.
|
27088857 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
|
27974663 |
2016 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide 3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression profiling.
|
27484095 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Here we show that H3K4me3 is increased in breast tumors driven by an activated PIK3CA allele and that inhibition of PI3K/AKT signaling reduces promoter-associated H3K4me3 in human breast cancer cells.
|
27292631 |
2016 |